Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BVXVOTCMKTS:CPMVNASDAQ:LIFENASDAQ:PTE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsCPMVMosaic ImmunoEngineering$0.49+37.1%$0.49$0.21▼$1.13$3.57M0.08265 shs200 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CPMVMosaic ImmunoEngineering0.00%+50.20%+81.43%-40.97%-13.42%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVXVBiondVax Pharmaceuticals 0.00N/AN/AN/ACPMVMosaic ImmunoEngineering 0.00N/AN/AN/ALIFEaTyr Pharma 0.00N/AN/AN/APTEPolarityTE 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.94) per shareN/ALIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00PTEPolarityTE$810K0.00N/AN/A$2.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/ACPMVMosaic ImmunoEngineering-$920K-$0.12N/A∞N/AN/AN/A-1,117.89%8/12/2025 (Estimated)LIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/APTEPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/ALatest LIFE, PTE, CPMV, and BVXV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A4/15/2025Q4 2024CPMVMosaic ImmunoEngineeringN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVXVBiondVax PharmaceuticalsN/A4.124.12CPMVMosaic ImmunoEngineeringN/A0.020.02LIFEaTyr Pharma0.026.076.07PTEPolarityTEN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVXVBiondVax Pharmaceuticals11.83%CPMVMosaic ImmunoEngineeringN/ALIFEaTyr Pharma61.72%PTEPolarityTE11.75%Insider OwnershipCompanyInsider OwnershipBVXVBiondVax Pharmaceuticals6.03%CPMVMosaic ImmunoEngineering80.99%LIFEaTyr Pharma3.70%PTEPolarityTE5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionablePTEPolarityTE427.38 million6.98 millionOptionableLIFE, PTE, CPMV, and BVXV HeadlinesRecent News About These CompaniesPioneering Technology Reports 2025 Q2 Financial ResultsMay 30, 2025 | thenewswire.comTMomentum Builds for ScanTech AI Systems at PTE Madrid 2025 as Industry Embraces AI-Powered SecurityApril 9, 2025 | globenewswire.comRegenetp Inc RGTPQApril 18, 2024 | morningstar.comMNEW INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PolarityTE, Inc. & Encourages Inves...January 10, 2024 | br.advfn.comRegenETP, Inc. (NJT.SG)January 6, 2024 | finance.yahoo.comPolarityTE Inc. [PTE] Investment Appeal on the RiseJune 14, 2023 | knoxdaily.comKPolarityTE Stock (NASDAQ:PTE), DividendsJune 9, 2023 | benzinga.comPolarityTE shares are trading lower after the company filed voluntary petitions for relief under Chapter 11.June 7, 2023 | benzinga.comPolarityTE, Inc. (PTE) stock price, news, quote & history – Yahoo FinanceMay 15, 2023 | uk.finance.yahoo.comSkin Replacement Market Recent Technological Advancements to ... - Digital JournalMay 4, 2023 | news.google.comNDismissal of Securities Claims Against Utah Biotech Company ... - JD SupraApril 29, 2023 | news.google.comNPolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You ... - NasdaqApril 25, 2023 | news.google.comNPolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 25, 2023 | finance.yahoo.comPolarityTE Avoids Lawsuit Over Skin Graft Product Disclosures - Bloomberg LawApril 20, 2023 | news.google.comNChronic Wound Care Market is expected to reach a valuation of US ... - Digital JournalApril 12, 2023 | news.google.comNForm DEF 14A ENERGY FUELS INC - StreetInsider.comApril 5, 2023 | news.google.comNPolarityTE Full Year 2022 Earnings: EPS Misses Expectations - Yahoo FinanceMarch 29, 2023 | news.google.comNPolarityTE Full Year 2022 Earnings: EPS Misses ExpectationsMarch 29, 2023 | finance.yahoo.comBiodexa Pharmaceuticals Stock (NASDAQ:BDRX), Quotes and ... - BenzingaMarch 28, 2023 | news.google.comNStocks That Hit 52-Week Lows On Tuesday - Sono Group (NASDAQ ... - BenzingaMarch 28, 2023 | news.google.comNMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeMarvell's New AI Chip Deals Capture Wall Street’s AttentionBy Jeffrey Neal Johnson | June 21, 2025View Marvell's New AI Chip Deals Capture Wall Street’s AttentionGE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsHSAs for Gym Memberships? These 3 Fitness Stocks Could SoarBy Chris Markoch | June 24, 2025View HSAs for Gym Memberships? These 3 Fitness Stocks Could SoarLIFE, PTE, CPMV, and BVXV Company DescriptionsBiondVax Pharmaceuticals NASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Mosaic ImmunoEngineering OTCMKTS:CPMV$0.49 +0.13 (+37.08%) As of 06/27/2025 03:05 PM EasternMosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.aTyr Pharma NASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.PolarityTE NASDAQ:PTEPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
